Silence Therapeutics (SLN) Enterprise Value (2019 - 2025)
Silence Therapeutics (SLN) has disclosed Enterprise Value for 7 consecutive years, with -$85.1 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 42.23% to -$85.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$85.1 million through Dec 2025, up 42.23% year-over-year, with the annual reading at -$85.1 million for FY2025, 42.23% up from the prior year.
- Enterprise Value hit -$85.1 million in Q4 2025 for Silence Therapeutics, up from -$122.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$64.3 million in Q4 2022 to a low of -$186.6 million in Q2 2025.
- Historically, Enterprise Value has averaged -$118.2 million across 5 years, with a median of -$113.2 million in 2023.
- Biggest five-year swings in Enterprise Value: tumbled 159.4% in 2021 and later skyrocketed 42.23% in 2025.
- Year by year, Enterprise Value stood at -$99.1 million in 2021, then soared by 35.14% to -$64.3 million in 2022, then crashed by 61.8% to -$104.0 million in 2023, then plummeted by 41.63% to -$147.3 million in 2024, then surged by 42.23% to -$85.1 million in 2025.
- Business Quant data shows Enterprise Value for SLN at -$85.1 million in Q4 2025, -$122.4 million in Q3 2025, and -$186.6 million in Q2 2025.